Ankylosing Spondylitis and Other Spondyloarthritides

Published on 27/03/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1372 times

Chapter 150 Ankylosing Spondylitis and Other Spondyloarthritides

The diseases collectively referred to as spondyloarthritides include ankylosing spondylitis (AS), arthritis associated with inflammatory bowel disease (IBD) and psoriasis, and reactive arthritis following gastrointestinal or genitourinary infections (see Table 150-1 on the Nelson Textbook of Pediatrics websiteimage at www.expertconsult.com). Pediatric rheumatologists have adopted the International League of Associations for Rheumatology (ILAR) classification scheme for juvenile idiopathic arthritis (JIA) and use the term enthesitis-related arthritis (ERA) to encompass most forms of spondyloarthritis in children, except those with co-existing psoriasis.

Clinical Manifestations

Axial and peripheral joint inflammation and enthesitis cause pain and swelling, localized tenderness, stiffness, and loss of range of motion. Common extra-articular manifestations include gastrointestinal inflammation even in the absence of overt IBD and ocular inflammation, which causes pain, erythema, and photophobia.

Enthesitis-Related Arthritis

Children are classified as having ERA if they have either arthritis and enthesitis or arthritis or enthesitis, with two of the following additional characteristics: (1) sacroiliac joint tenderness or inflammatory lumbosacral pain (see Table 150-1), (2) the presence of HLA-B27, (3) age > 6 yr and male sex, (4) acute anterior uveitis, and (5) a family history of an HLA-B27–associated disease (ERA, sacroiliitis with IBD, reactive arthritis, or acute anterior uveitis) in a first-degree relative. Patients with psoriasis (or a family history of psoriasis in a first-degree relative), a positive rheumatoid factor (RF) test result, or systemic arthritis are excluded from this group. Many children with ERA go on to eventually have AS, but many do not, and it is not currently possible to determine whose ERA will progress.

Juvenile Ankylosing Spondylitis

JAS frequently begins with oligoarthritis and enthesitis. The arthritis occurs predominantly in the lower extremities and often involves the hips, in contrast to oligoarticular JIA. Also unlike in adult-onset AS, in JAS axial involvement is usually absent until later in the disease course (Fig. 150-1). Enthesitis is particularly common, manifesting as localized and often severe tenderness at characteristic tendon (as well as ligament, fascia or capsule) insertions around the plantar surface of the foot, ankle (Achilles), and knee (patella). The disease course is variable and can include periods of low disease activity. Fever and weight loss are uncommon and, if present, raise the possibility of IBD.

Diagnosis

Spondyloarthritis is suggested by the onset of oligoarthritis and/or enthesitis in an older boy. The arthritis predominantly affects hips, knees, ankles, and feet (often the intertarsal joints). When the axial skeleton is involved, patients may experience inflammatory back pain, which is characterized by nighttime pain and considerable morning stiffness that is improved by activity and worsened by rest (Table 150-2). With progressive disease there is a loss of the normal lumbar lordosis, inability to touch the toes with the legs straight, and sacroiliac pain on palpation or with pelvic compression. AS is diagnosed if there is sufficient radiographic evidence of sacroiliitis and the patient meets at least one clinical criterion involving inflammatory back pain, limitation of motion in the lumbar spine, or limitation of chest expansion. JAS is present if the patient is <16 yr. The term juvenile-onset AS is frequently used to describe AS when the symptoms begin before age 16 yr but full criteria for a diagnosis are not met. Because radiographic evidence of sacroiliitis can take 10 yr or longer to develop and clinical manifestations may be subtle, it can be difficult to differentiate spondyloarthritis from JIA early in the disease course. Efforts to establish criteria that are more sensitive for diagnosing axial spondyloarthritis with MRI and use of other clinical features and markers are underway.

In a child with chronic arthritis, the presence of erythema nodosum, pyoderma gangrenosum, fever, weight loss, or anorexia suggests IBD. The onset of arthritis following a recent history of diarrhea, and symptoms of urethritis or conjunctivitis may suggest reactive arthritis. Psoriasis, nail changes (see Fig. 150-2), or a family history of psoriasis suggests psoriatic arthritis. Early differentiation between the various forms of spondyloarthritis by laboratory or radiographic means is difficult. Sacroiliac joint involvement or enthesitis, including adjacent bone marrow edema, may be seen on MRI, and results of a technetium Tc 99m bone scan may be positive, but results of the latter examination are often difficult to interpret in children and adolescents.

Treatment

The aims of therapy for JAS are to control inflammation, minimize pain, preserve function, and prevent ankylosis (fusion of adjacent bones) using a combination of anti-inflammatory medications, physical therapy, and education. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen (15-20 mg/kg/day), are frequently used initially and may reduce bony progression if used continually. With relatively mild disease such as might be present in ERA, NSAIDs can be helpful when used along with intra-articular corticosteroids (e.g., triamcinolone hexacetonide) to control peripheral joint inflammation. However, for JAS, it is typically necessary to add a second-line agent. Sulfasalazine (up to 50 mg/kg/day; maximum 3 gm/day) or methotrexate (10 mg/m2) may be beneficial for peripheral arthritis, but these medications have not been shown to improve axial disease in adults. Biologics that inhibit tumor necrosis factor-α (TNF-α) (etanercept, infliximab, adalimumab) have been efficacious in reducing symptoms and improving function in adults with AS, and there is evidence that similar responses are seen in children. TNF inhibitors have not been shown to halt bony progression in established AS, underscoring the need for earlier recognition and better therapies.

Physical therapy and low-impact exercise should be included in the treatment program for all children with spondyloarthritis. Exercise to maintain range of motion in the back, thorax, and affected joints should be instituted early in the disease course. Custom-fitted insoles are particularly useful in management of painful entheses around the feet, and the use of pillows to position the lower extremities while the child is in bed can be helpful.